3 Best ETFs With 50%+ Upside to Buy in August 2026, According to Analysts
Analysts see a few thematic ETFs that stand out this August for investors seeking long‑run growth in digital assets and healthcare. These include t...
Crinetics Pharmaceuticals Inc. (CRNX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 741,553 | $27,748,912 | -3% | 0.01% |
| 2. | Fifth Lane Capital Cavan Copeland | 0 | $0 | 0% | |
| 3. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% | |
| 4. | Walleye Capital Will England | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.06 | 5,000 | $110,300.00 | 5,000 | 2023-06-08 | Filing | |
| $22.22 | 157,515 | $3,499,983.30 | 5,321,032 | 2022-04-18 | Filing | |
| $19.80 | 1,200,000 | $23,760,000.00 | 5,163,517 | 2021-10-25 | Filing | |
| $16.44 | 304,136 | $4,999,995.84 | 3,963,517 | 2021-04-08 | Filing | |
| $13.10 | 4,000 | $52,400.00 | 4,000 | 2020-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 3,000 | $120,000.00 | 19,225 | 2026-07-02 | Filing | |
| $36.22 | 608 | $22,021.76 | 6,400 | 2026-06-17 | Filing | |
| $35.62 | 6,292 | $224,121.04 | 7,008 | 2026-06-17 | Filing | |
| $40.10 | 85,163 | $3,415,036.30 | 105,289 | 2026-04-08 | Filing | |
| $37.77 | 3,961 | $149,606.97 | 112,018 | 2026-03-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,758,938 | $365,179,474 | 0.01% | |
| 2. | 2,689,350 | $100,635,477 | 0% | |
| 3. | 2,075,375 | $77,572,984 | 0.07% | |
| 4. | 820,395 | $30,699,181 | 0.04% | |
| 5. | 393,688 | $14,731,807 | 0% |
News See All
10 Affordable Biotech Stocks to Buy Right Now
On July 6, BioPharma Dive reported that drug developers producing new medicines for the treatment of autoimmune disorders and cancer accounted for more than 40% of venture financing rounds in the first...
Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback?
TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target.
10 Best Innovative Healthcare Stocks to Buy Now
The U.S. healthcare sector has lagged behind the entire market for three consecutive years, with returns of just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock Positioned for Growth After Promising Atumelnant Clinical Results?
TheFly reported on June 14 that at ENDO 2026, CRNX presented Phase 2 data from its TouCAHn study evaluating investigational atumelnant in adults with classic congenital adrenal hyperplasia (CAH).
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
10 Best Mid-Cap Stocks That Could Double Your Money
In this article, we will take a look at some of the best mid-cap stocks that are currently offering at least 100% upside potential to investors. On June 13, CNBC reported that U.S.
10 Best AI Driven Biotech Stocks to Invest In
In this article, we will take a look at some of the best AI driven biotech stocks that are currently offering attractive upside potential.
10 Under-the-Radar Stocks with Massive Upside for 2026
The benchmark 10-year Treasury yield hit its highest level since January 2025 that same week, while the 30-year yield briefly touched its highest since 2007, Reuters reported.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2026 Earnings Call Transcript
Operator: Hello, everyone. Thank you for joining us, and welcome to the Crinetics Pharmaceuticals First Quarter 2026 Financial Results.
Hedge Fund Resource Center